Wells Fargo & Company Galectin Therapeutics Inc Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Wells Fargo & Company holds 14,376 shares of GALT stock, worth $39,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,376

Previous 14,368 0.06%

Holding current value

$39,102

Previous $32,000 21.88%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.04 - $2.86 $16 - $22	8 Added 0.06%	14,376 $39,000
Q2 2024 Aug 13, 2024	BUY	$2.13 - $4.2 $15,152 - $29,878	7,114 Added 98.07%	14,368 $32,000
Q1 2024 May 10, 2024	SELL	$1.6 - $2.44 $524 - $800	-328 Reduced 4.33%	7,254 $17,000
Q4 2023 Feb 09, 2024	SELL	$1.6 - $2.18 $728 - $991	-455 Reduced 5.66%	7,582 $12,000
Q3 2023 Nov 13, 2023	BUY	$1.38 - $1.97 $3,571 - $5,098	2,588 Added 47.49%	8,037 $15,000
Q2 2023 Aug 15, 2023	SELL	$1.32 - $2.08 $27,362 - $43,116	-20,729 Reduced 79.18%	5,449 $7,000
Q1 2023 May 12, 2023	BUY	$1.1 - $2.4 $21,745 - $47,445	19,769 Added 308.46%	26,178 $54,000
Q4 2022 Feb 13, 2023	SELL	$1.03 - $1.66 $2,176 - $3,507	-2,113 Reduced 24.79%	6,409 $7,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $7 - $14	-6 Reduced 0.07%	8,522 $13,000
Q2 2022 Aug 12, 2022	BUY	$1.19 - $1.74 $28 - $41	24 Added 0.28%	8,528 $11,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.31 $1 - $2	1 Added 0.01%	8,504 $13,000
Q4 2021 Feb 14, 2022	BUY	$2.07 - $3.8 $12 - $22	6 Added 0.07%	8,503 $18,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $9,176 - $14,703	-3,543 Reduced 29.43%	8,497 $33,000
Q2 2021 Aug 16, 2021	SELL	$2.07 - $5.1 $17,156 - $42,268	-8,288 Reduced 40.77%	12,040 $39,000
Q1 2021 May 13, 2021	SELL	$1.96 - $2.57 $149,914 - $196,571	-76,487 Reduced 79.0%	20,328 $45,000
Q4 2020 Feb 09, 2021	BUY	$2.24 - $2.87 $88,639 - $113,568	39,571 Added 69.13%	96,815 $217,000
Q3 2020 Nov 05, 2020	SELL	$2.53 - $3.64 $27,076 - $38,955	-10,702 Reduced 15.75%	57,244 $153,000
Q2 2020 Aug 13, 2020	BUY	$1.66 - $3.15 $36,998 - $70,207	22,288 Added 48.82%	67,946 $209,000
Q1 2020 May 14, 2020	BUY	$1.51 - $3.0 $68,943 - $136,974	45,658 New	45,658 $89,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.57M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $162M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Galectin Therapeutics Inc Transaction History